Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA ... Read More
Quanterix launches diagnostic test aiding early Alzheimer’s detection
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed to aid in the evaluation of patients ... Read More
Sage Therapeutics strikes $3.1bn licensing deal with biogen for depression and neurological disorder treatments
Sage Therapeutics has entered into a high-stakes global collaboration and licensing agreement with Biogen, valued at up to $3.1 billion, aimed at advancing two promising ... Read More
Convelo, Genentech to collaborate on remyelination drugs for MS
US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs ... Read More
Prevacus partners with Blinktbi for advanced concussion drug trials
Prevacus, a leading US biopharmaceutical company, has announced a strategic partnership with medical device company Blinktbi, utilizing their novel EyeStat device to measure brain function ... Read More